Natural Killer Cell Therapeutics Market - Global Forecast 2026-2032

The Natural Killer Cell Therapeutics Market is advancing rapidly as breakthroughs in cell engineering and immuno-oncology fuel new opportunities for clinical impact and commercial growth. Executive stakeholders are navigating operational, regulatory, and strategic complexities to capture value across a dynamic competitive landscape.

Market Snapshot: Natural Killer Cell Therapeutics

The Natural Killer Cell Therapeutics Market grew from USD 533.35 million in 2025 to USD 571.11 million in 2026, with an expected CAGR of 7.27% that will drive the market to USD 872.26 million by 2032. This trajectory reflects robust investment, accelerated technological innovation, and an expanding pipeline of clinical programs targeting oncology, autoimmune, and infectious disease applications.

Scope & Segmentation

Therapeutic Approaches: Allogeneic (off-the-shelf, universal donor constructs) and autologous (personalized patient-specific) therapies shape manufacturing and clinical strategies.
Indication Targets: Programs address hematological malignancies (leukemia, lymphoma, multiple myeloma), broad solid tumors (including breast, lung, and ovarian cancer), autoimmune conditions, and infectious diseases.
Source Materials: Cell lines (e.g., KHYG-1, NK-92), induced pluripotent stem cells, peripheral and umbilical cord blood support diverse development models.
End User Dynamics: Hospitals, academic research centers, contract research and manufacturing organizations, and independent research entities drive demand for scalable solutions.
Geographic Reach: The Americas, EMEA, and Asia-Pacific regions each contribute unique clinical, regulatory, and manufacturing advantages, shaping development site selection and market access strategies.
Technology Platforms: Engineered NK receptor constructs, gene editing, ex vivo expansion, and advanced manufacturing tools are enabling programmable effector functions and enhanced tumor targeting.

Key Takeaways for Senior Decision-Makers

Scientific advances in NK cell biology are supporting translation from proof-of-concept innovations to scalable, clinically relevant therapies.
Investors and strategists must weigh the trade-offs between allogeneic off-the-shelf models for broad access versus autologous therapies’ personalized potential.
Operational priorities are shifting toward manufacturing resilience, standardized potency assays, and strengthened supply chain strategies, particularly in response to evolving regulatory clarity.
Regional policy and reimbursement diversity require sponsors to adapt commercialization plans, prioritize nearshoring, and strategically determine trial and manufacturing locations.
Partnerships among pioneers, pharmaceutical firms, and specialized CDMOs accelerate access to late-stage development, distribution, and commercial infrastructure, optimizing competitive positioning.

Tariff Impact on Cell Therapy Supply Chains

Recent tariff adjustments implemented in 2025 have driven up procurement costs for critical equipment and single-use consumables, increasing development capital requirements. Tariffs also complicate international clinical supply logistics, prompting organizations to re-evaluate sourcing models, supplier networks, and manufacturing location choices. Some firms address these pressures by strengthening domestic capacity, negotiating localized supply agreements, and forging strategic partnerships with regional CDMOs to maintain momentum despite added cost and complexity.

Methodology & Data Sources

This report applies a mixed-methods research approach combining in-depth interviews with clinical, regulatory, and manufacturing experts alongside review of peer-reviewed publications, clinical registries, patent filings, and industry disclosures. Analytical cross-verification aligns expert insights with secondary data, ensuring robust, actionable intelligence.

Why This Report Matters

Enables executive teams to anticipate technological, operational, and regulatory trends shaping the next phase of natural killer cell therapeutics development.
Supports strategic investment decisions by clarifying comparative advantages of different development models, sourcing strategies, and partnership structures.
Informs risk mitigation by highlighting the effects of tariffs and regional dynamics on supply chain resilience and program scalability.

Conclusion

Effective commercialization of NK cell therapeutics requires aligning scientific innovation with operational execution, adaptive risk management, and cross-sector collaboration. Stakeholders who integrate platform advances, manufacturing scale, and regulatory clarity will be positioned to drive clinical impact and sustainable growth.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Natural Killer Cell Therapeutics Market, by Therapy Type

8.1. Allogeneic NK Cell Therapy
8.2. Autologous NK Cell Therapy
8.3. CAR-NK Cell Therapy
8.4. NK Cell Engager Biologics
8.5. Cytokine-Induced NK Cell Therapy

9. Natural Killer Cell Therapeutics Market, by Cell Source

9.1. Cell Line
9.1.1. KHYG-1
9.1.2. NK-92
9.2. Induced Pluripotent Stem Cells
9.3. Peripheral Blood
9.4. Umbilical Cord Blood

10. Natural Killer Cell Therapeutics Market, by Application

10.1. Autoimmune Disease
10.2. Hematological Malignancies
10.2.1. Leukemia
10.2.2. Lymphoma
10.2.3. Multiple Myeloma
10.3. Infectious Disease
10.4. Solid Tumors
10.4.1. Breast Cancer
10.4.2. Lung Cancer
10.4.3. Ovarian Cancer

11. Natural Killer Cell Therapeutics Market, by End User

11.1. Research Organizations
11.2. Hospitals
11.3. Specialty Clinics

12. Natural Killer Cell Therapeutics Market, by Region

12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific

13. Natural Killer Cell Therapeutics Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Natural Killer Cell Therapeutics Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. United States Natural Killer Cell Therapeutics Market
16. China Natural Killer Cell Therapeutics Market

17. Competitive Landscape

17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Nektar Therapeutics
17.6. ImmunityBio, Inc. by NantWorks LLC
17.7. Nkarta, Inc.
17.8. Takeda Pharmaceutical Company Limited
17.9. Century Therapeutics, Inc.
17.10. Celularity Inc.
17.11. Merck KGaA
17.12. BioHaven Pharmaceutical Holding Company Ltd. by Pfizer Inc.
17.13. Sanofi S.A.
17.14. Innate Pharma S.A.
17.15. Cytovia Therapeutics, Inc.
17.16. Fate Therapeutics, Inc.
17.17. Fortress Biotech, Inc.
17.18. Acepodia Inc.
17.19. Affimed N.V.
17.20. Agenus Inc.
17.21. Cytovac A/S
17.22. Dragonfly Therapeutics, Inc.
17.23. Emercell SAS by Onward Therapeutics SA
17.24. Gamida Cell Ltd. by Ayrmid Ltd.
17.25. Glycostem Therapeutics B.V.
17.26. iCell Gene Therapeutics LLC
17.27. Multimmune GmbH
17.28. PersonGen BioTherapeutics
17.29. Phio Pharmaceuticals Inc.
17.30. Regeneron Pharmaceuticals Inc.

List of Figures

FIGURE 1. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY ALLOGENEIC NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY ALLOGENEIC NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY ALLOGENEIC NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY AUTOLOGOUS NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY AUTOLOGOUS NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY AUTOLOGOUS NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CAR-NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CAR-NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CAR-NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK CELL ENGAGER BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK CELL ENGAGER BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK CELL ENGAGER BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CYTOKINE-INDUCED NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CYTOKINE-INDUCED NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CYTOKINE-INDUCED NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY KHYG-1, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY KHYG-1, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY KHYG-1, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK-92, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK-92, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY NK-92, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY PERIPHERAL BLOOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY PERIPHERAL BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY UMBILICAL CORD BLOOD, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY UMBILICAL CORD BLOOD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY UMBILICAL CORD BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 114. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 116. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 117. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 118. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 119. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 120. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 121. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 132. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 133. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 134. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 135. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 136. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 137. AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 149. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 150. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 151. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 152. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 153. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 154. ASEAN NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 157. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 158. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 159. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 160. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 161. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 162. GCC NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 173. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 174. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 175. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 176. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 177. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 178. BRICS NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 181. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 182. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 183. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 184. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 185. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 186. G7 NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 188. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 189. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 190. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 191. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 192. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 193. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 194. NATO NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 197. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 198. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 199. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 200. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 201. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 204. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 205. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 206. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 207. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY CELL LINE, 2018-2032 (USD MILLION)
TABLE 208. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 209. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 210. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 211. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Natural Killer Cell Therapeutics market report include:

Nektar Therapeutics
ImmunityBio, Inc. by NantWorks LLC
Nkarta, Inc.
Takeda Pharmaceutical Company Limited
Century Therapeutics, Inc.
Celularity Inc.
Merck KGaA
BioHaven Pharmaceutical Holding Company Ltd. by Pfizer Inc.
Sanofi S.A.
Innate Pharma S.A.
Cytovia Therapeutics, Inc.
Fate Therapeutics, Inc.
Fortress Biotech, Inc.
Acepodia Inc.
Affimed N.V.
Agenus Inc.
Cytovac A/S
Dragonfly Therapeutics, Inc.
Emercell SAS by Onward Therapeutics SA
Gamida Cell Ltd. by Ayrmid Ltd.
Glycostem Therapeutics B.V.
iCell Gene Therapeutics LLC
Multimmune GmbH
PersonGen BioTherapeutics
Phio Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.

Table Information

Report Attribute	Details
No. of Pages	187
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 571.11 Million
Forecasted Market Value ( USD ) by 2032	$ 872.26 Million
Compound Annual Growth Rate	7.2%
Regions Covered	Global
No. of Companies Mentioned	27

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3511EUR$3,939USD£3,045GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3787EUR$4,249USD£3,285GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5133EUR$5,759USD£4,452GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6212EUR$6,969USD£5,387GBP

Market Snapshot: Natural Killer Cell Therapeutics

Scope & Segmentation

Key Takeaways for Senior Decision-Makers

Tariff Impact on Cell Therapy Supply Chains

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Natural Killer Cell Induction Culture Kit Market Report: Trends, Forecast and Competitive Analysis to 2031

Natural Killer Cells Therapeutics - Global Strategic Business Report

IPSC Derived NK Cells- Pipeline Insight, 2025

NK Cell Therapies - Pipeline Insight, 2025

Natural Killer (NK) Cell Therapeutics Market Report 2025